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http://dx.doi.org/10.1016/j.stemcr.2017.08.019SUMMARYLowering total tau levels is an attractive therapeutic strategy for Alzheimer’s disease and other tauopathies. High-throughput screening
in neurons derived from human induced pluripotent stem cells (iPSCs) is a powerful tool to identify tau-targeted therapeutics. How-
ever, such screens have been hampered by heterogeneous neuronal production, high cost and low yield, andmulti-step differentiation
procedures. We engineered an isogenic iPSC line that harbors an inducible neurogenin 2 transgene, a transcription factor that rapidly
converts iPSCs to neurons, integrated at the AAVS1 locus. Using a simplified two-step protocol, we differentiated these iPSCs into
cortical glutamatergic neurons with minimal well-to-well variability. We developed a robust high-content screening assay to identify
tau-lowering compounds in LOPAC and identified adrenergic receptors agonists as a class of compounds that reduce endogenous
human tau. These techniques enable the use of human neurons for high-throughput screening of drugs to treat neurodegenerative
disease.INTRODUCTION
The microtubule-associated neuronal protein tau stabi-
lizes microtubules and mediates axon outgrowth and
axonal transport. Abnormal tau is strongly implicated in
Alzheimer’s disease (AD) and other neurodegenerative
tauopathies (Wang and Mandelkow, 2016). Although in-
traneuronal aggregates of insoluble tau fibrils, known as
neurofibrillary tangles, are a hallmark of tauopathies and
correlate with cognitive decline in AD (Nelson et al.,
2012), soluble tau may also play a key pathogenic role
(Brunden et al., 2008; Spires-Jones et al., 2011). In
Drosophila and mouse models, overexpression of wild-
type human tau induces neurodegeneration (Wittmann
et al., 2001), axonopathy (Spittaels et al., 1999), and
extensive cell death (Andorfer et al., 2005) independently
of tangle formation. In two regulatable tauopathy mouse
models, suppressing soluble tau expression resulted in
memory recovery (Santacruz et al., 2005; Sydow et al.,
2011) and stabilized neuron numbers (Santacruz et al.,
2005) without reducing the level of neurofibrillary tan-
gles, suggesting that soluble forms of tau promote neuro-
degeneration. Lowering endogenous tau levels reduces
amyloid b (Ab)-induced behavioral deficits in AD mouse
models (Roberson et al., 2007; Vossel et al., 2010), and
lowering total tau levels by inhibiting tau acetylation orStem Cell Report
This is an open access article under the Cphosphorylation rescues tau-related memory deficits in
PS19 transgenic mice (Lasagna-Reeves et al., 2016; Min
et al., 2015). Since tau knockout mice appear to be cogni-
tively normal, lowering total tau levels in neurons appears
to be safe and will likely have a high therapeutic index
(Morris et al., 2013). Thus, soluble tau is a promising
therapeutic target. However, identifying selective, non-
toxic tau-lowering compounds has proven to be difficult
(Gruninger, 2015).
Cell-based ‘‘phenotypic’’ high-throughput screening
(HTS) is a powerful unbiased tool to identify gene targets
or small-molecule compounds exerting desired effects.
However, HTS requires large numbers of cells and has
been largely restricted to immortalized human neuronal
lines, such as neuroblastoma SH-SY5Y(Jain et al., 2012)
and gliomaH4 (Albrecht et al., 2004) cells, or non-neuronal
lines, such as HeLa cells (Fatokun et al., 2013). Since these
cells differ physiologically from post-mitotic neurons, hits
identified in these cells might not work in neurons. This
may be particularly true for tau, a neuronal protein that is
abundant in axons but is mainly expressed in the cytosol
in non-neuronal cells (Uberti et al., 1997). Rodent primary
neurons are more physiologically relevant, but challenges
in scalability preclude their use for HTS, and certain com-
pounds may differ in activity between human and rodent
cells.s j Vol. 9 j 1221–1233 j October 10, 2017 j ª 2017 The Author(s). 1221
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Engineering of i3N iPSCs and Generation of Homogeneous Functional Glutamatergic Neurons by a Simplified Two-Step
Procedure
(A) Schematic of the targeting of the AAVS1 locus with pUCM.Puro-CAG.rtTA3G-TRE3G.Ngn2 donor vector by TALEN-mediated integration.
The third-generation doxycycline-inducible reverse transcriptional activator (rtTA3G) is driven by the CAG promoter and followed by
rbGlob polyA tail. Mouse Ngn2 is driven by the tet response element (TRE3G) and followed by SV40 polyA tail. It is oriented tail-to-tail with
(legend continued on next page)
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Human induced pluripotent stem cells (iPSCs) are a
promising alternative because they can be used to generate
large numbers of subtype-specific human neurons that are
relevant to neurodegenerative disease. However, iPSC-
derived neurons currently have limited utility in HTS as-
says (D’Aiuto et al., 2014), as traditional differentiation
methods are difficult to scale up and usually yield a hetero-
geneous population of neurons and glia-like cells over a
protracted timeline (Muratore et al., 2014; Nicholas et al.,
2013). More homogeneous neuronal populations can be
produced by overexpressing pro-neuronal transcription
factors (Chanda et al., 2014; Pang et al., 2011). Neurogenin
2 (NGN2)-induced neurons from various human embry-
onic stem cell and iPSC lines show robust morphological,
transcriptional, and functional homogeneity (Busskamp
et al., 2014; Zhang et al., 2013). However, this method
has shortcomings for HTS. First, it entails a labor-intensive
multi-step differentiation procedure that is difficult to
apply to microplates. Second, it is subject to cell-to-cell
and well-to-well variability due to different viral infection
and puromycin selection rates, uneven cell distribution,
which might affect cell survival and image quantification,
and experiment-to-experiment variability due to differ-
ences in viral titers and qualities of primary mouse glia
from different batches. Third, it is costly to scale up.
In this study, we engineered a clonal iPSC line that stably
harbors a doxycycline-inducible mouse Ngn2 transgene at
an adeno-associated virus integration site 1 (AAVS1) safe-
harbor locus. This integrated, inducible, and isogenic
Ngn2 iPSC line (i3N) can be differentiated into functional
glutamatergic cortical neurons by a simplified two-step dif-
ferentiation protocol. We developed a robust high-content
screening (HCS) assay to identify tau-lowering compounds
and discovered compounds that target adrenergic receptor
(AR) pathways to lower endogenous human tau.rtTA3G. Orange boxes are exons of the PPP1R12C gene; gray boxes are
junction PCR screening and generate 1.1-kb and 1.5-kb PCR products,
detect the nonintegrated allele at the AAVS1 locus.
(B) Flow diagram of the two-step procedure for generating i3Neurons
(C) Representative phase-contrast images during the differentiation
50 mm.
(D) Representative images showing immunocytochemical staining for
NeuN in i3Neurons after 4 weeks of differentiation. Nuclei were label
(E) Representative images of immunocytochemical staining of mature
an axon identified by the axon initiation segment marker ankyrin G (
(F) Representative confocal images of i3Neurons showing immunola
receptors (red) and the presynaptic vesicular glutamate transporter VG
glutamatergic synapses formed between i3Neurons. Scale bar, 5 mm.
(G) Representative traces of action potentials evoked by 500-ms curren
at a higher firing frequency (black trace).
(H) Spontaneous excitatory postsynaptic currents recorded from an i3
(bottom).
See also Figures S1 and S2.RESULTS
Engineered iPSCs for Scalable Production of
Homogeneous Excitatory Neurons
Lentivirus-mediatedNGN2 expression induces rapid differ-
entiation of iPSCs into excitatory neurons (Zhang et al.,
2013). To avoid viral transduction-induced toxicity and
variability in NGN2 expression, we engineered isogenic
iPSC lines with an integrated Ngn2 expression cassette. A
doxycycline-inducible Ngn2 transgene was integrated
into the AAVS1 safe harbor of a well-characterized control
human iPSC line (WTC11) (Miyaoka et al., 2014) by
TALEN-mediated integration of a donor cassette contain-
ing a puromycin-resistance gene (Figure 1A). Six puromy-
cin-resistant clones were picked, and integration of
the Ngn2 transgene into the AAVS1 locus was confirmed
with two sets of primers (PCR1 and PCR2) (Figures 1A
and S1A). Transgene integration into both alleles was
confirmed by the absence of the wild-type allele, deter-
mined by a third set of primers (PCR3) (clones 1 and 4).
These iPSC clones have isogenic, integrated, and inducible
NGN2 expression (i3N); neurons derived from them
are called i3Neurons. Further characterization of clone 1
in the absence of doxycycline showed homogeneous
expression of the pluripotency markers OCT4, SOX2,
and TRA-1-81, indicating no leakage of NGN2 expression
(Figure S1B). The cells also had a normal karyotype
(Figure S1C).
i3N iPSCs could be differentiated into functional excit-
atory neurons by the published multi-step differentiation
protocol. To overcome the poor scalability and reproduc-
ibility of this procedure when adapted to the HTS plat-
form, we established a simplified two-step protocol
(Figure 1B). After doxycycline induction and subplating,
pre-differentiated i3Neurons became post-mitotic, andregions of homology. PCR1 and PCR2 primers are used for 50 and 30
respectively. PCR3 primers (product size, 248 base pairs) are used to
.
of i3Neurons. The timeline is the same as shown in (B). Scale bar,
the pan-neuronal marker MAP2, bIII tubulin (TUJ1 antibody), and
ed by Hoechst. Scale bar, 25 mm.
8-week-old i3Neurons show tau enrichment (detected with HT7) in
AnkG). Nuclei were labeled by Hoechst. Scale bar, 25 mm.
beling of postsynaptic GluR2/3 containing AMPA-type glutamate
lut1 (green). The colocalization of GluR2/3 and VGlut1 puncta marks
t step injections at just above the firing threshold (green trace) and
N neuron (top) were blocked by CNQX, an AMPA receptor antagonist
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exhibited neuron-like morphology in less than 7 days and
mature neuronal morphology within 3–4 weeks in the
absence of glia (Figure 1C). Differentiated neuron mar-
kers bIII tubulin (TUJ1), microtubule-associated protein 2
(MAP2), and neuronal nuclei antigen (NeuN)were detected
in i3Neurons after 4 weeks of maturation (Figure 1D). The
absence of Olig2-positive oligodendrocytes or glial fibril-
lary acidic protein (GFAP)-positive astrocytes confirmed
the purity of the neuronal population (Figure S2A).
In 8-week-old i3Neurons, tau was abundant in axons
identified by the presence of a single axonal initial segment
(AIS), as detected with ankyrin G staining (Kordeli et al.,
1995) (Figure 1E). More than 90% of i3Neurons contained
AIS, supporting the notion that they exhibit mature polar-
ity by 8 weeks (Figure S2B). Tau expression had little over-
lap with MAP2, a dendritic marker (Figure 1E). Both
three-repeat (3R) and four-repeat (4R) tau were detected
(Figure S2C). Tau in i3Neurons were also highly phosphor-
ylated, compared with healthy human brain (Figure S2D).
Importantly, all i3Neurons expressed vesicular glutamate
transporter 1 (VGlut1), a marker of glutamatergic neurons,
and were GABA negative, indicating a homogeneous popu-
lation of excitatory glutamatergic neurons (Figure S2E).
The punctate distribution of synapsin-1 staining along
the processes revealed abundant synapse formation (Fig-
ure S2F). When co-cultured with glia, i3Neurons had
mature synapses that contained juxtaposed pre- and post-
synaptic markers of glutamatergic synapses (Figure 1F).
Whole-cell patch-clamp recordings showed action poten-
tial firing in response to current injections (Figure 1G).
Spontaneous postsynaptic currents detected in i3Neurons
were blocked byCNQX, anAMPA receptor antagonist, con-
firming functional glutamatergic synaptic transmission
(Figure 1H).
i3Neurons Cultured in Microplates Show
Homogeneous Gene Expression with Low Variability
Two key determinants of reliable HTS are scalability and
minimal well-to-well variability. We were able to produce
large quantities of i3Neurons via i3N iPSC proliferation
and a pre-differentiation step. Subsequent subplating en-
ables i3Neurons culture in 96- and 384-well microplates
with even cell distribution (Figure 1B). To determine
whether i3Neurons homogeneously differentiate in micro-
plates, we quantified the expression of multiple neuronal
and glial genes of 4-week-old cells from 12 randomly
selected wells of a 96-well plate by RT-qPCR (Figure 2).
Consistently high levels of pan-neuronal genes, AMPA re-
ceptor genes, glutamate transporter genes, synaptic genes,
and CUX1, a marker of cortical layer 2/3 neurons, were
observed in all 12 wells, suggesting a uniform differentia-
tion of glutamatergic cortical neurons. In addition, all the
i3Neurons showed low expression of twomarkers of neural1224 Stem Cell Reports j Vol. 9 j 1221–1233 j October 10, 2017progenitor cells, PAX6 and NESTIN, indicating that they
were fully differentiated. Ngn2 was undetectable, as ex-
pected in the absence of doxycycline. No markers of glial
cells or of GABAergic neurons (e.g., GAD65/67) were de-
tected, but the GABA receptors GABRA2 and GABRB1
were expressed at low levels. Thus, i3Neurons can be
cultured in microplates with low well-to-well variability
and are suitable for HTS.
Optimization of an HCS Assay to Screen
for Tau-Lowering Compounds
Lowering tau levels has emerged as a key therapeutic op-
portunity in AD. To our knowledge, no HCS targeting
endogenous tau has been performed in post-mitotic hu-
man neurons. Because i3Neurons are scalable and highly
homogeneous, they are an ideal system to screen for tau-
targeted therapeutics. Taking advantage of the highly spe-
cific anti-human tau antibody HT7, we set out to develop
a 384-well format HCS assay to detect endogenous tau
levels in i3Neurons (Figure 3A). Total tau levels were deter-
mined by immunoreactivity of HT7 normalized to bIII
tubulin intensity in a corresponding well (HT7/TUJ1) (Fig-
ure 3B). The background signal, measured inwells omitting
HT7, was more than 10-fold lower than those with HT7
(Figures 3B and S3A). The optimal seeding density was
2,000 cells/well (Figure S3A). Neuronal health was judged
from neurite total length (Figure S3B) and valid nucleus
count (Figure S3C), two highly correlated health parame-
ters (Figure S3D) that are widely used (Harrill et al., 2013;
K Hancock et al., 2015). Treatment with a tau-specific
siRNA reduced the total tau levels in a dose-dependent
manner (Figures 3C and 3D), whereas increased total tau
levels were detected when i3Neurons were infected by
AAV human tau (Figures S3E and S3F), confirming assay
specificity and sensitivity. Salicylate, YM-01, and methy-
lene blue reduce total tau levels (Abisambra et al., 2013; Ho-
sokawa et al., 2012; Min et al., 2015). All three compounds
reduced the HT7/TUJ1 signal in a time-dependent manner
accompanied by a mild yet significant reduction of neurite
total length (Figure 3E). The Z0 factor, ameasure of the assay
response window (Zhang et al., 1999) and determined by
values of control and hTau siRNA, was 0.41, supporting
the robustness of the HCS assay.
Identification of Tau-Lowering Compounds via HCS
Next, we used the HCS assay to screen LOPAC (Library of
Pharmacologically Active Compounds) for tau-lowering
compounds. This library contains 1,280 bioactive small
molecules, including inhibitors, receptor ligands,marketed
drugs, and pharmaceutically relevant structures, that affect
most signaling pathways and cover major drug target clas-
ses. Since overwhelming majority compounds did not
change tau levels (Figure 4A), we used sample compounds
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Figure 2. i3Neurons Show Homogeneous
Expression of Glutamatergic Cortical
Neuronal Genes
Heatmap of RT-qPCR analysis of expression
levels of genes listed on the right. Expres-
sion levels are normalized to housekeeping
gene GAPDH (expressed as DCt) and color
coded as shown. mRNA was harvested
from 12 random wells of 4-week-old i3Neu-
rons cultured in a 96-well plate. See also
Table S1.as their own control and calculated Z scores based on
LOPAC compounds on each plate (Brideau et al., 2003).
Compounds that changed tau (as judged from the HT7/
TUJ1 ratio) were defined as hits if their Z scores were greater
than 3 or less than 3, a stringent cut-off correlates to a p
value of 0.00135 (Zhang et al., 2006). All hits were then
ranked by neuronal health parameters, including neurite
total length (Figure 4B) and valid nucleus count (Figure 4C).
The top two tau-lowering hits that show least cytotox-
icity, measured by neurite total length and valid nucleuscount, are two functionally related AR agonists, moxoni-
dine and metaproterenol (Figures 4B and 4C). To validate
these hits, we adapted a sensitive human tau ELISA
that uses HT7 as the capture antibody and Tau5 as the
detection antibody (Meredith et al., 2013). The dynamic
range of the assay was >3,000, and the detection limit
was 10.7 pg/mL (Figure 5A). This assay readily detected
siRNA-induced reduction of endogenous human tau
by >50% (Figure 5B). We then confirmed that moxonidine,
clonidine (a moxonidine-related adrenergic agonist), andStem Cell Reports j Vol. 9 j 1221–1233 j October 10, 2017 1225
AB
E
C
D
Accell hTau siRNA(μM)
H
T7
/T
U
J1
(%
)
N
eu
r it
e  
to
ta
l l
en
gt
h 
(%
)
H
T7
/T
U
J1
(%
)
YM-01Salicylate Methylene BlueDMSO
N
eu
rit
e 
to
ta
l l
e n
gt
h 
(%
)
YM-01Salicylate Methylene BlueDMSO
+Anti-HT7 & TUJ1
Ta
u
TU
J1
hTau siRNA 0.5μM hTau siRNA 1μMControl siRNA
Accell hTau siRNA(μM)
+Anti-TUJ1 Only
Primary Antibody
TU
J1
N
eu
rit
e 
Tr
ac
in
g
Ta
u
N
eu
rit
e 
M
as
ki
ng
Background Well Control Well
 i3Neurons
in 384-well plate
3days 
Compound Incubation
Automated 
Immunostaining
18days maturation
Image Acquisition 
&  Analysis
24hr
48hr
72hr
0 0.5 1
0
25
50
75
100
125
0 0.5 1
0
25
50
75
100
125
****
****
####
0
25
50
75
100
125
****
****
***
****
****
****
####
#
####
#
***
****
****
****
****
****
****
####
####
###
####
####
####
0
25
50
75
100
125
***#
Figure 3. Development and Validation of an HCS Assay to Detect Tau Levels in i3Neurons
(A) Schematic of the HCS assay optimized to measure cellular tau levels in neurons treated with small-molecule compounds.
(B) Representative fluorescence high-content images showing tau (green) and bIII tubulin (white) channels from a background well (left,
anti-TUJ1 only) and a control well (right, anti-HT7 and TUJ1). Neurite regions (purple) were traced according to the TUJ1 channel and
were applied to the tau channel with the neuronal profiling module of Cellomics software. Scale bar, 10 mm.
(C) Representative fluorescence high-content images showing tau (green) and bIII tubulin (white) channels from i3Neurons after 7 days of
treatment with control siRNA or human tau siRNA (0.5 or 1 mM). Scale bar, 50 mm.
(D) Automated quantification of human tau levels (left) and neurite total length (right) from i3Neurons treated with human tau siRNA.
Data are from three independent experiments, total N = 42 per treatment; values are means ± SEM relative to control siRNA. ****p <
0.0001 compared with control siRNA, STATA mixed model. ####p < 0.0001, STATA mixed model.
(E) Automated quantification of human tau levels (left) and neurite total length (right) from i3Neurons treated with 5 mM salicylate, 1 mM
YM-01, or 1.5 mM methylene blue for 24–72 hr. Data are from three independent experiments, total N = 42 per treatment; values are
means ± SEM relative to DMSO. ***p < 0.001, ****p < 0.0001, compared with DMSO, STATA mixed model; #p < 0.05, ###p < 0.001, ####p <
0.0001, comparison between three time points within each compound treatment, STATA mixed model.
See also Figure S3.
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Figure 4. Primary Screening and Hit Se-
lection from LOPAC
(A) Overview of automated quantification of
human tau levels from i3Neurons incubated
with compounds from LOPAC at 10 mM for
3 days (green triangles). The library was
distributed to three and one-half 384-well
plates; each plate contains 16 control wells
(DMSO, orange circles) and 16 background
wells (blue diamonds). Results are shown as
the Z score, calculated based on LOPAC
compounds on each plate. Compounds
above (yellow triangles) and below (red
triangles) the cut-offs of +3 or 3 (dotted
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(B and C) Hits are ranked by neurite total
length (B) and valid nucleus count (C). Re-
sults are shown as Z score, calculated based
on LOPAC compounds on each plate. Mox-
onidine and metaproterenol are the top two
tau-lowering hits from both rankings.metaproterenol reduced tau levels in a dose-dependent
manner. None of the three compounds induced a signifi-
cant loss of bIII tubulin, as measured with a bIII tubulin
ELISA, indicating a lack of toxicity (Figures 5C–5E).
Additional pharmacologic modulators of a- and b-AR
activity were used to further confirm the involvement of
a- and b-adrenergic signaling in modulating endogenous
human tau levels. i3Neurons were treated with nonselec-
tive a- or b-AR agonists (dexmedetomidine or isoproter-
enol) and their respective antagonists. Activation of a- or
b-ARs significantly reduced endogenous human tau levels,
and inhibition by nonselective antagonists caused tau
accumulation (Figures 5F and 5G). Moreover, the tau-
lowering effects of moxonidine and metaproterenol were
abolished by pre-incubationwith the corresponding antag-
onists (atipomezole and propranol, respectively) (Figures
5F and 5G). The ability of a- or b-AR agonists to reduce
endogenous tau levels was further confirmed in an inde-
pendent line of i3Neurons (Figures S4A and S4B). Our
results showed that activation of a- and b-adrenergicsignaling pathways could represent tau-lowering therapeu-
tic strategies in human neurons.DISCUSSION
In this study, we integrated a doxycycline-inducible mouse
Ngn2 cassette into the AAVS1 locus and established iPSC
lines that can be converted efficiently to a uniform popula-
tion of glutamatergic neurons by a simplified two-step pro-
tocol. We then developed a robust, scalable, and simple
HCS assay and used it to identify compounds that lower
tau in post-mitotic human neurons. This proof-of-princi-
ple screen identified AR agonists as a class of compounds
that decrease endogenous human tau levels.
i3Neurons have several features that make them suitable
for HTS, particularly imaging-based HCS. First, the popula-
tion of differentiated neurons is homogeneous, whichmay
reflect the uniform genetic background of the clonal
i3N iPSCs. As all of the iPSC-derived cells are neurons,Stem Cell Reports j Vol. 9 j 1221–1233 j October 10, 2017 1227
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Figure 5. Activation of a- and b-AR Re-
duces Total Tau Levels in i3Neurons
(A) Representative calibration curve of HT7-
Tau5 ultra-sensitive human tau ELISA. Inset
shows the assay’s limit of quantification
(LOQ).
(B) 7-day incubation of human tau siRNA
significantly lowered total tau levels in
i3Neurons. Human tau levels were quantified
by HT7-Tau5 ELISA and normalized to protein
level. Values are means ± SEM relative to
control siRNA. Data are from one experiment,
N = 6 wells per treatment.
(C–E) Concentration-response curve of mox-
inidine (C), clonidine (D), and metaproter-
enol (E) determined by HT7-Tau5 ELISA.
Insets show the bIII tubulin level for each
concentration as determined by bIII tubulin
ELISA. Both tau and bIII tubulin levels are
normalized to protein levels. Values are
means ± SEM relative to DMSO control. Data
are from four independent experiments per-
formed in triplicate (C, N = 12 per concen-
tration) and three independent experiments
performed in triplicate (D and E, N = 9 per
concentration). *p < 0.05, **p < 0.01, ***p <
0.001; STATA mixed model.
(F and G) 3-day incubation with moxonidine
(30 mM) and the a-AR agonist dexmedeto-
midine (100 mM) (F) or metaproterenol
(30 mM) and the b-AR agonist isoproterenol
(30 mM) (G) significantly reduced total
tau levels in i3Neurons. The a-AR antag-
onist atipamezole (100 mM) (F) and the
b-AR antagonist propranolol (50 mM) (G)
increased total tau levels and abolished the
tau-lowering effect of moxonidine (F) or
metaproterenol (G), respectively. Human tau
levels were quantified by HT7-Tau5 ELISA and
normalized to protein level. Values are means
± SEM relative to DMSO control. Data are from
three independent experiments performed in
triplicate (F, N = 9 per treatment) and four
independent experiments performed in trip-
licate (G, N = 12 per treatment) ***p < 0.001,
STATA mixed model.
See also Figure S4.
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sensitivity and specificity of HTS screens is increased. Other
safe-harbor loci besides the AAVS1 locus (e.g., citrate lyase
beta-like) can be used in human iPSCs (Cerbini et al.,
2015). By targeting multiple safe-harbor sites with P2A or
IRES elements, it may be possible to integrate multiple
inducible transcription factors to differentiate iPSCs into
other neuronal subtypes, such as dopaminergic neurons
(Amamoto and Arlotta, 2014) or motor neurons (Hester
et al., 2011), for use in HTS. Second, our simplified glia-
free differentiation protocol overcomes hurdles, such as
scalability, variability, complexity, and cost, that previously
hindered the use of iPSC-derived neurons in drug discovery
pipelines. For example, instead of generating and freezing
large quantities of neuronal precursor cells, our approach
involves a single cost-effective 3-day pre-differentiation
procedure. The pre-differentiated neurons are post-mitotic
and can be subplated onto poly-D-lysine/laminin-coated
microplates with high consistency. Differentiation of
i3Neurons does not require viral infection, puromycin se-
lection, or frequent medium change, thereby reducing
the possibility of introducing variability and contamina-
tion during HTS. Thus, standardized HTS procedures can
be established regardless of location, time, or users, facili-
tating future use of i3Neurons for ultra-HTS of large libraries
of chemical compounds.
Tau-targeted approaches have been proposed as an alter-
native therapeutic strategy for AD and other tauopathies
(Dehdashti et al., 2013; DeVos et al., 2013; Panza et al.,
2016). Previous tau-targeted small-molecule strategies—
including kinase inhibitors against hyperphosphorylated
tau, tau aggregation inhibitors, microtubule stabilizers,
and compounds that enhance clearance of tau aggre-
gates—have had limited success (Brunden et al., 2009;
Gruninger, 2015; Medda et al., 2016; Min et al., 2015;
Panza et al., 2016). Lowering total tau levels may have
beneficial effects. For example, the MAPT H1c haplotype
increases tau expression and is associated with increased
risk of progressive supranuclear palsy, corticobasal degener-
ation, and AD (Baker et al., 1999; Di Maria et al., 2000;
Myers et al., 2005, 2007). Tau lowering in transgenicmouse
models rescued functional deficits and tau-mediated neu-
rodegeneration (Andrews-Zwilling et al., 2010; Ittner
et al., 2010; Lasagna-Reeves et al., 2016; Min et al., 2015;
Roberson et al., 2007, 2011; Vossel et al., 2010) and appears
to be safe (Morris et al., 2013). However, discovering com-
pounds that reduce total tau levels has been challenging.
Tau is natively unstructured and has proved a difficult
target for rational drug design. Several tau-lowering candi-
dates that reduce tau gene transcription were identified by
small-scale screening with in-cell western analysis (Dickey
et al., 2006). AlphaLISA and homogeneous time-resolved
fluorescence assays were used in SH-SY5Y cells to screen
for tau-lowering compounds (Dehdashti et al., 2013). How-ever, these studies were done and validated only in tumor
cell lines that lack well-defined axons highly enriched in
tau. Previous tau-lowering compounds also caused signifi-
cant cytotoxicity (Dehdashti et al., 2013). In addition, the
regulation of tau homeostasis may differ in rodent and hu-
man neurons. Indeed, methylene blue, which reduces the
levels of human tau overexpressed inmouse neurons in vivo
and in vitro (Congdon et al., 2012; Hosokawa et al., 2012),
had minor effect in human neurons in our assay.
Using i3Neurons in a robust HCS assay, we identified AR
agonists as a class of tau-lowering compounds. Both a- and
b-AR signaling appeared to regulate tau levels in similar
fashion, as AR activation led to tau reduction and AR
inhibition led to tau accumulation. Besides moxonidine
hydrochloride (a-adrenergic agonist) and metaproterenol
hemisulfate (b-adrenergic agonist), threeothera- orb-adren-
ergic agonists (clonidine, dexmedetomidine, and isoproter-
enol) also reduced tau levels in human neurons. The tau-
lowering effects of moxonidine and metaproterenol were
abolished by their corresponding antagonists atipomezole
and propranol, which elevated tau levels by themselves. In
agreementwith our findings, the selective b2-AR antagonist
ICI 118,551 increased tau phosphorylation and accumula-
tion in an AD mouse model (Branca et al., 2014). Paradoxi-
cally, genetic suppression of b2-ARs reduced tau pathology
(Wisely et al., 2014). One likely explanation could be that
complete removal of b2 AR prevented harmful effects of
dysregulated b2-ARs, such as binding to Ab.
Deficiency in a- or b-AR signaling has been implicated in
AD. Levels of high-affinity a2-ARs are markedly reduced in
AD patients (Pascual et al., 1992). Polymorphisms of b-ARs
are linked to increased risk of late-onset AD (Yu et al., 2008).
The natural ligand of ARs is norepinephrine, whose major
source in the CNS is noradrenergic neurons in the locus co-
eruleus (LC); these neurons project widely to the forebrain,
which includes two regions especially affected by tauopa-
thies, the hippocampus and neocortex (Mather andHarley,
2016). Patients with AD have significant degeneration of
neurons in the LC and much lower levels of norepineph-
rine. Interestingly, abnormal tau lesions emerged predom-
inantly in LC regions even in individuals in their 20s, 30s,
and 40s (Braak and Del Trecidi, 2015; Braak et al., 2011),
suggesting that low levels of norepinephrine in the LC
may lead to tau accumulation in young susceptible people
and can eventually propagate to other brain regions.
How adrenergic signaling affects tau homeostasis is not
known. Interestingly, some AR-modulating compounds
may have a beneficial effect that is independent of their
AR agonist activities. For example, norepinephrine and
isoproterenol, whose chemical backbones contain 1,2-di-
hydroxybenzene, reduce insoluble tau levels by directly
binding cysteine residues in tau to prevent tau oligomeriza-
tion, independent of their AR agonist activities (SoedaStem Cell Reports j Vol. 9 j 1221–1233 j October 10, 2017 1229
et al., 2015). Modulating adrenergic signaling could affect
other aspects of AD pathology as well. Chronic activation
of b-ARs increases Ab production (Ni et al., 2006) and pro-
tects against the detrimental effects of Ab on hippocampal
function (Li et al., 2013). AR activation also reduces lipo-
polysaccharide-induced expression of tumor necrosis fac-
tor alpha in microglia (Schlachetzki et al., 2010; Szabo
et al., 1997) and interferon-g-induced expression of class
II antigens in astrocytes (Frohman et al., 1988). More
studies are needed to dissect the molecular mechanisms
underlying the role of adrenergic signaling in AD and to
further validate AR agonists as a potential therapeutic strat-
egy for AD and related tauopathies.EXPERIMENTAL PROCEDURES
Chemicals and Reagents
Allmedium, reagents, and supplements for iPSC culture and differ-
entiation were from Invitrogen unless otherwise specified. Doxy-
cycline, DMSO, cytosine b-D-arabinofuranoside (Ara-C), salicylate,
LOPAC library, AR agonists and antagonists, and electrophysiology
related chemicals were from Sigma.Generating and Selecting i3N iPSC Clones
Ngn2 transgenewas subcloned to a pUCMdonor vector containing
an AAVS1 homology arm. The Tet-ON 3G-controlled Ngn2 trans-
gene was integrated to the AAVS1 locus of human iPSC lines
through a TALEN nuclease pair. Genomic DNA from puromycin-
selected and expanded clones were purified and genotyped
by three PCR reactions. We generated i3N iPSC lines from two
independent wild-type genetic background human iPSC lines:
WTC11 (Miyaoka et al., 2014) and F12486.13 (female, white, age
at biopsy 48 years, reprogrammed by Sendai virus, generated by
Dr. Celeste Karch, Washington University in St. Louis). The iPSC
protocol was approved by the Committee on Human Research at
the University of California, San Francisco (15-15798). A detailed
protocol is described in Supplemental Experimental Procedures.i3Neuron Differentiation
i3Neurons were differentiated with a simplified two-step protocol
(pre-differentiation and maturation). For pre-differentiation,
i3N iPSCs were incubated with doxycycline (2 mg/mL) for 3 days
at a density of 2.0–2.5 3 106 cells/well in six-well plates coated
with Matrigel in knockout Dulbecco’s modified Eagle’s medium
(KO-DMEM)/F12 medium containing N2 supplement, non-essen-
tial amino acids (NEAA), mouse laminin (0.2 mg/mL), brain-
derived neurotrophic factor (BDNF, 10 ng/mL), neurotrophin-3
(NT3,10 ng/mL; Peprotech), and Y-27632. The medium was
changed daily, and Y-27632 was removed from day 2. For matura-
tion, pre-differentiated i3N precursor cells were dissociated,
counted, and subplated at the desired density on plates coated
with poly-D-lysine (PDL)/laminin inmaturationmedium contain-
ing 50% DMEM/F12, 50% Neurobasal-A medium, 0.53 B27 sup-
plement, 0.53 N2 supplement, GlutaMax, NEAA, mouse laminin
(1 mg/mL), BDNF (10 ng/mL), and NT3 (10 ng/mL). Half of the1230 Stem Cell Reports j Vol. 9 j 1221–1233 j October 10, 2017medium was replaced on day 7 and again on day 14, and the me-
dium volume was doubled on day 21. Thereafter, one-third of
themediumwas replacedweekly until the cells were used. For elec-
trophysiological recording, i3N precursor cells were subplated on
Matrigel-coated coverslips, and mouse glia were added on day 1
in maturation medium containing 5% heat-inactivated fetal
bovine serum and 2 mM Ara-C.
Immunocytochemistry
i3N iPSCs or i3Neurons in coverslips were fixed with conditioned
medium containing 4% paraformaldehyde, permeabilized with
0.1%TritonX-100, and incubated for 1 hr in blocking solution con-
taining PBS, 0.01% Triton X-100, and 5% normal goat serum. The
cells were then incubated in blocking solution containing primary
antibody overnight at 4C, followed by incubation with secondary
antibody for 1 hr. Images were acquired with an LSM880 confocal
system (Zeiss) with Airyscan and a 203 or 633 oil-immersion objec-
tive lens. Antibodies used for immunocytochemistry were those
against SOX2 (sc-17320S; Santa Cruz Biotechnology), OCT4 (sc-
5279; Santa Cruz Biotechnology), TRA-1-81 (sc-21706; Santa Cruz
Biotechnology), MAP2 (AB5622 or MAB3418; Millipore), VGlut1
(MAB5502; Millipore), bIII tubulin (TUJ1; Aves Labs), neuronal nu-
clear antigen (MAB377; Millipore), GABA (A2052; Sigma), HT7
(MN1000; Thermo Fisher), ankyrin G (N106/36; NeuroMa), synap-
sin-1 (D12G5; Cell Signaling), Olig2 (AB9610; Millipore), GFAP
(MAB3402; Millipore), and GluR2/3 (AB1506; Millipore).
Reverse Transcription and Real-Time qPCR
i3Neurons were cultured in 96-well PDL plates (655946, Greiner) at
a density of 10,000 cells/well for 4 weeks. cDNA from 12 random
wells was obtained with Cells-to-CT Kits (Ambion) as recommen-
ded by the manufacturer. qPCR reactions were done in duplicate
with SYBR Green Real-Time PCR master mixes (Applied Bio-
systems) and the Applied Biosystems 7900HT fast real-time PCR
system. All the primers (Table S1) have been validated with human
brain RNA (Zhang et al., 2013). RNAswithout reverse transcription
were used as negative control, and the dissociation curve fromeach
gene was reviewed to ensure the desired amplification. Expression
levels were normalized to GAPDH.
HCS Assay to Determine Total Tau Levels
After pre-differentiation, i3N precursor cells were placed in 384-well
plates at a density of 2,000 cells/well. Fresh maturation medium
was added weekly. On day 18, human tau siRNA, known tau-
lowering compounds (salicylate, YM-01, and methylene blue) and
1,280 compounds from LOPAC were added and incubated at
the desired final concentration for the desired amount of time.
Human tau, recognized by HT7 antibody, total neurites, recognized
by bIII tubulin antibody (TUJ1; Aves Labs) and nuclei, recognized
by Hoechst were detected by a semi-automated immunostaining
procedure. A fully automated ArrayScan high-content system
(Thermo) was used to acquire images and quantify total tau levels.
See Supplemental Experimental Procedures for detailed methods.
Human Tau and bIII Tubulin ELISA
Sensitive human tau and bIII tubulin ELISAs were adapted and
modified according to previous reports (Barten et al., 2011;
Meredith et al., 2013). Briefly, mousemonoclonal antibodyHT7 or
rabbit monoclonal bIII tubulin antibody (ab68193; Abcam) was
used for capture. The respective analytes were detected with alka-
line phosphatase-conjugated mouse monoclonal antibodies Tau5
or TUJ1 (806401, 801201; BioLegend). Recombinant full-length
human tau (rPeptide) and recombinant bIII tubulin (Cytoskeleton)
were used to generated standard curves for each assay. The CDP-
Star substrate (T2214, Invitrogen) was used as a chemiluminescent
alkaline phosphatase substrate. See Supplemental Experimental
Procedures for detailed methods.Statistics
The sample size for each experiment was determined on the basis
of previous experience. Differences between means were assessed
by unpaired Student’s t test (GraphPad Prism, v. 6.0) or multilevel
mixed-effects linear regression model (STATA12; StataCorp), as
indicated. Values are reported as means ± SEM. The Shapiro-Wilk
test of normality and F test to compare variances were applied to
datasets when applicable.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.08.
019.
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